Genomic Oncology Research Group, Department of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Medical Oncology Group, Department of Molecular Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Trends Cancer. 2024 Jun;10(6):519-530. doi: 10.1016/j.trecan.2024.02.003. Epub 2024 Mar 7.
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10-20% collectively. Frequent damaging and truncating somatic mutations indicate a tumour-suppressive role of KMT2C/D in breast oncogenesis. Recent studies using cell lines and mouse models to replicate KMT2C/D loss show that these genes contribute to oestrogen receptor (ER)-driven transcription in ER breast cancers through the priming of gene enhancer regions. This review provides an overview of the functions of KMT2C/D and outlines the recent clinical and experimental evidence of the roles of KMT2C and KMT2D in breast cancer development.
KMT2C 和 KMT2D 是组蛋白赖氨酸甲基转移酶,负责在基因增强子位点上将组蛋白 3 赖氨酸 4(H3K4)残基单甲基化。KMT2C/D 是乳腺癌中最常发生突变的组蛋白甲基转移酶(HMTs),总发生率为 10-20%。频繁的破坏性和截断性体细胞突变表明 KMT2C/D 在乳腺癌发生中具有肿瘤抑制作用。最近使用细胞系和小鼠模型复制 KMT2C/D 缺失的研究表明,这些基因通过基因增强子区域的启动,有助于雌激素受体(ER)驱动的 ER 乳腺癌中的转录。本文综述了 KMT2C/D 的功能,并概述了最近关于 KMT2C 和 KMT2D 在乳腺癌发生中的作用的临床和实验证据。